Clinical Trial - Trial HKUCTR-2922
Access comprehensive clinical trial information for HKUCTR-2922 through Pure Global AI's free database. This Phase 3 trial is sponsored by Merck Sharp & Dohme (Asia) Ltd. and is currently Recruitment Completed. The study focuses on Neoplasm.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to HKU CLINICAL TRIALS REGISTRY data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
HKUCTR-2922
Phase 3
Recruitment Completed
drug
Trial Details
HKU CLINICAL TRIALS REGISTRY • HKUCTR-2922
Untitled Trial
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies
Study Focus
Sponsor & Location
Merck Sharp & Dohme (Asia) Ltd.
China
Timeline & Enrollment
Phase 3
N/A
Oct 15, 2021
ICD-10 Classifications
Neoplasms
Benign neoplasms
In situ neoplasms
Personal history of other neoplasms
Benign neoplasm: Other specified sites
Data Source
HKU CLINICAL TRIALS REGISTRY
HKUCTR-2922
Non-Device Trial